DySiS Medical Ltd was able to complete GBP7.4 Million or US$11 million on a round of capital infusion. Investors who participated in the round are Scottish Investment Bank who is the investment representative of Scottish Enterprise, NBGI, Albion Ventures and Lundbeckfond Ventures.

The majority of the capital infusion came from Lundbeckfond, a Copenhagen-based investment group that specializes in Life Sciences, who invested GBP 6 million. The remaining GBP 1.4 million was put-up through its existing stockholders Scottish Investment Bank (SIB), Albion Ventures and NBGI.

Casper Breum and Mikael Strindlund who are from Lundbekfond Ventures will be joining the board of directors of DySiS Medical. "DySIS Medical's technology offers substantial clinical benefits in the fight against cervical cancer as well as improved cost-effectiveness over existing care. We believe DySIS is a compelling business to invest in," commented Strindlund.

Cervical Cancer is extremely preventable as long as it is detected in its early stages of development. The Scotland based DySiS Medical is into development and selling of the DySIS colposcope. The system has shown a significantly improved accuracy in detecting cervical cancer at its early stages of development. In August 2012, the UK National Institute for Health and Clinical Excellence has recommended the purchase of the system.